Tevogen Bio Holdings Inc. - Common Stock TVGN 深 沪
等待开盘 08-08 09:30:00 美东时间
0.8691
-0.083
-8.75%
华盛通- 最 高1.01
- 今 开0.9548
- 成交量 169.80万股
- 最 低 0.8571
- 昨 收 0.9524
- 总市值 1.60亿
- 52周最高 3.09
- 市盈率 静 --
- 换手率 0.92%
- 52周最低 0.2556
- 委 比 -89.60%
- 总股本 1.84亿
- 历史最高 21.09
- 量 比 0.50
- 振 幅 16.05%
- 历史最低 0.2556
- 每 手 1
- 风险率 2.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
Tevogen Bio Holdings Inc. has received $1 million in funding to advance its Tevogen.AI drug discovery initiative, part of a potential $10 million grant from KRHP LLC. The company is well-capitalized, enabling it to execute its growth strategy. The funding will enhance AI capabilities for faster drug development and improved patient access, following the recent patent publication of its machine learning technology for predicting immunologically ac...
08-07 13:00
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
Tevogen reports a 60% increase in institutional ownership of its common stock from December 2024 to March 2025, with Vanguard and BlackRock contributing 151% growth. 73% of 51 institutional holders increased or maintained positions, reflecting significant new investor interest. Tapan Shah highlights confidence in the company's fundamentals and long-term potential, citing advancements in Tevogen.AI, collaborations with Microsoft and Databricks, an...
08-06 19:59
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Tevogen.AI is collaborating with Microsoft and Databricks to develop the beta version of its PredicTcell model, incorporating oncology data to enhance accuracy and diversity. The initiative aims to accelerate cancer immunotherapy development while expanding external market opportunities. Enhanced analytics and visualization tools are being developed to support internal R&D. These efforts build on a recent international patent for novel machine le...
08-05 18:32
Tevogen Bio To Receive $1M Grant To Advance AI-Driven Drug Discovery Platform, Part Of $10M Non-Dilutive Funding From KRHP
Funds will support advancement of Tevogen.AI, the Company's artificial intelligence–driven drug discovery initiative.The $1 million is part of up to $10 million in previously announced non‑dilutive grant funding from
08-02 03:37
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
Tevogen Bio Holdings Inc. announced it expects to receive $1 million in grant funding to advance Tevogen.AI, its artificial intelligence-driven drug discovery program. This funding is part of up to $10 million in non-dilutive grants from KRHP LLC. The company plans to use the funds to enhance target discovery, reduce development timelines, and improve treatment accessibility.
08-01 19:30
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
Tevogen, a biopharmaceutical company, announced that its executive officers and board members collectively own over 74% of its outstanding shares. This significant insider ownership reflects their strong belief in the company's mission and long-term strategy. CEO Dr. Ryan Saadi highlighted the team's control over decision-making, enabling continued rapid growth and innovation in developing off-the-shelf T cell therapeutics for infectious diseases...
07-30 16:41
Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
<p>Tevogen Bio Holdings Inc. (Nasdaq: TVGN) welcomes the U.S. government's "AI Action Plan," emphasizing domain-specific standards and healthcare AI innovations. The company highlights its collaboration with Microsoft and Databricks to develop PredicTcell™, a machine learning model that accelerates immunotherapy research and reduces drug development costs. CEO Ryan Saadi stresses AI's potential to lower treatment costs and improve access to healt...
07-28 15:52
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
Tevogen has announced the publication of its international patent application by WIPO, titled "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models." The technology, developed by Tevogen.AI with support from Microsoft and Databricks, aims to identify peptides with strong immune interactions for targeted therapies against diseases like cancers and infectious diseases. Traditional methods often fail to acc...
07-18 16:36
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
<p>WARREN, N.J., July 17, 2025 – Tevogen Bio Holdings Inc. (Nasdaq: TVGN) announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey, previously occupied by Pfizer and Cordis. The facility will support the company's cell therapy manufacturing operations, aligning with its strategic goals of accelerating clinical development, maintaining cost efficiency, and scalability. The lease term is expected to be over f...
07-17 13:15
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
<p>Tevogen Bio announced the deployment of PredicTcell™, an AI-driven platform, to analyze patient data and enhance clinical trial efficiency. Supported by Microsoft and Databricks, Tevogen.AI aims to identify suitable patients quickly, reducing trial timelines and accelerating therapy development. This initiative supports the company's goal of delivering cost-effective personalized T-cell therapies while improving commercial viability and shareh...
07-16 15:57
